Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SC-003 |
Synonyms | |
Therapy Description |
Tamrintamab pamozirine (SC-003) is a monoclonal anti-tumor-associated antigen (TAA) antibody in conjugation with an undisclosed cytotoxic agent, which may target TAA-expressing tumor cells (PMID: 32513564). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SC-003 | SC003|SC 003|Tamrintamab pamozirine | Tamrintamab pamozirine (SC-003) is a monoclonal anti-tumor-associated antigen (TAA) antibody in conjugation with an undisclosed cytotoxic agent, which may target TAA-expressing tumor cells (PMID: 32513564). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02539719 | Phase I | Budigalimab + SC-003 SC-003 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | Terminated | USA | 0 |